| Bioactivity | VX-150 is an orally active, highly selective NaV1.8 inhibitor. VX-150 has the potential for various pain indications research[1]. | ||||||||||||
| Invitro | VX-150 is an orally bioavailable pro-drug that rapidly converts into its active moiety, which is a highly selective inhibitor of NaV1.8 relative to the other sodium channel subtypes (>400-fold)[1]. | ||||||||||||
| Name | VX-150 | ||||||||||||
| CAS | 1793080-72-4 | ||||||||||||
| Formula | C21H17F4N2O7P | ||||||||||||
| Molar Mass | 516.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hemme J Hijma, et al. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults. Pain Med. 2021 Aug 6;22(8):1814-1826. |
VX-150
CAS: 1793080-72-4 F: C21H17F4N2O7P W: 516.34
VX-150 is an orally active, highly selective NaV1.8 inhibitor. VX-150 has the potential for various pain indications res
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.